Home › NDC Lookup › RxCUI directory › RxCUI 2630760

Atorvastatin 4 MG/ML Oral Suspension — RxCUI 2630760

RxNorm drug concept · Semantic clinical drug
RxCUI 2630760 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2630760
Official nameAtorvastatin 4 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asatorvastatin (as atorvastatin calcium) 20 MG per 5 ML Oral Suspension; atorvastatin calcium 20 MG in 5 mL Oral Suspension
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)1,207 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Atorvastatin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It lowers LDL cholesterol and triglycerides when used with diet. It also lowers the risk of heart attack and stroke in adults who have CHD or are at higher risk, including people w...
  • Take it by mouth once a day. Any time of day works, and you can take it with or without food. Pick a time you will remember. If you miss a dose, one label says to skip it and take...
  • Common ones include stuffy nose, joint or muscle aches, diarrhea, upset stomach, and trouble sleeping. Many people have few problems. If muscle pain is unexplained or comes with we...
  • Call for unexplained muscle pain, tenderness or weakness, especially with fever. Also call for yellow skin or eyes, or signs of a serious allergy like facial swelling or a blisteri...
📖 Read our full Atorvastatin guide →

🕸️ Concept Web — How Atorvastatin 4 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Atorvastatin 4 MG/ML Oral Suspension RxCUI 2630760

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Atorvastatin 83367
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Atorvaliq 2631862
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Atorvastatin Oral Suspension 2630759
    • Atorvastatin Oral Liquid Product 2630758
    • Atorvastatin Oral Product 1158284
    • Atorvastatin Oral Suspension [Atorvaliq] 2631866
    • Atorvaliq Oral Liquid Product 2631865
    • Atorvaliq Oral Product 2631864
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Atorvastatin 4 MG/ML 2630757
    • Atorvastatin 4 MG/ML Oral Suspension [Atorvaliq] 2631867
    • Atorvastatin 4 MG/ML [Atorvaliq] 2631863

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Atorvastatin 4 MG/ML SCDC · 2630757
  • Atorvastatin Oral Suspension SCDF · 2630759
  • Atorvastatin Oral Liquid Product SCDG · 2630758
  • Atorvastatin Oral Product SCDG · 1158284

Brand-Name Concepts

  • Atorvastatin 4 MG/ML Oral Suspension [Atorvaliq] SBD · 2631867
  • Atorvastatin 4 MG/ML [Atorvaliq] SBDC · 2631863
  • Atorvastatin Oral Suspension [Atorvaliq] SBDF · 2631866
  • Atorvaliq Oral Liquid Product SBDG · 2631865
  • Atorvaliq Oral Product SBDG · 2631864
  • Atorvaliq BN · 2631862

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2630760 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
46287-0030-01 150 mL in 1 BOTTLE (46287-030-01) ATORVALIQ CMP Pharma, Inc. 2023-03-01
Observed labelers: CMP Pharma, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$1.1876
Range $1.1876–$1.1876 · middle 50% $1.1876–$1.1876 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.